I've been researching Celiac disease and Thiamine deficiency for a long time. Recently I found information that shows a relationship between the lack of Thiamine and Celiac Disease pathogenesis. What do you think?
Thiamine is used in the mitochondria to produce energy (ATP) in the body for cells use as they go about their various functions. Various chemical reactions take place as the glucose moves through the transport chain in the mitochondria. Oxygen is needed at the end of the transport chain to pick up electrons leftover from the chemical reactions of ATP production and combines with Hydrogen electrons to form water. One molecule of glucose results in 32-36 ATP.
If there is not enough Thiamine for the mitochondria to produce ATP using Oxygen to mop up the spare electrons, the mitochondria switches to anaerobic (without oxygen) production of energy. Only 2 ATP are produced in this manner from one glucose molecule. Anaerobic production of ATP leaves lactic acid as a byproduct. Oxygen delivered to the cell passes through unused or is ignored since it's not capable of being used. This induces a state of hypoxia. Thiamine deficiency causes hypoxia.
Hypoxia-Inducible Factor 1 alpha (HIF-1a) is part of a checks and balances system within cells. HIF-1a is degraded (turned off) by byproducts from aerobic production of energy using thiamine. However, if the byproducts build up too much, HIF-1a is stimulated. During low oxygen levels and anaerobic production of ATP, a build up of lactic acid stimulates HIF-1a.
Hypoxia-Inducible Factor 1α binds to thiamine transporter SLC19A3 and activates it to increase thiamine uptake.
HIF-1a affects genes in the nucleus, entering through micro-pores. HIF-1α signaling triggers the release of inflammatory cytokines and increases inflammatory cell proliferation. It can also cause cell death.
Hypoxia and high levels of HIF-1a are found in many autoimmune diseases and cancer.
Thiamine attenuates HIF-1a signaling. Thiamine restores ATP production to aerobic production.
Here's an excerpt...
"HIF-1α shows its functions through translocating into the nucleus, dimerizing with HIF-1β and binding to hypoxia-responsive elements of the HIF-1α target genes. Recent data have also suggested that HIF-1α plays a role in maintaining intestinal epithelial barrier functions [37,38]. Accumulating evidence has also shown that HIF-1 α plays an essential role in cells via interaction with the NF-kB p65 pathway in the pathogenesis of inflammation [17]. In addition, previous research has further reported that HIF-1α expression is increased in the duodenal tissue of celiac disease patients [19,39]. It has been pointed out that activated HIF-1α is involved in celiac disease pathogenesis.".
https://pmc.ncbi.nlm.nih.gov/articles/PMC9954839/
References:
Increased Expression of Hypoxia-Inducible Factor 1α in Coeliac Disease
https://www.nature.com/articles/pr2010143
Intestinal parameters of oxidative imbalance in celiac adults with extraintestinal manifestations
https://pmc.ncbi.nlm.nih.gov/articles/PMC5703914/
Emerging role of hypoxia-inducible factor-1α in inflammatory autoimmune diseases: A comprehensive review
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1073971/full
Thiamine deficiency activates hypoxia inducible factor-1α to facilitate pro-apoptotic responses in mouse primary astrocytes
https://pmc.ncbi.nlm.nih.gov/articles/PMC5646851/
Stabilization of the hypoxia-inducible transcription Factor-1 alpha (HIF-1α) in thiamine deficiency is mediated by pyruvate accumulation
https://pubmed.ncbi.nlm.nih.gov/30008376/
Thiamine (Vitamin B1)-An Essential Health Regulator
https://pmc.ncbi.nlm.nih.gov/articles/PMC12251314/
https://pubmed.ncbi.nlm.nih.gov/40647310/
Role of HIF-1α in the Hypoxia Inducible Expression of the Thiamine Transporter, SLC19A3
https://pmc.ncbi.nlm.nih.gov/articles/PMC5097002/
https://pubmed.ncbi.nlm.nih.gov/27743994/
Thiamine insufficiency induces Hypoxia Inducible Factor-1α as an upstream mediator for neurotoxicity and AD-like pathology
https://pubmed.ncbi.nlm.nih.gov/36241022/
Mito-Nuclear Communication by Mitochondrial Metabolites and Its Regulation by B-Vitamins
https://pmc.ncbi.nlm.nih.gov/articles/PMC6379835/
The role of hypoxic microenvironment in autoimmune diseases
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1435306/full
Emerging role of hypoxia-inducible factor-1α in inflammatory autoimmune diseases: A comprehensive review
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1073971/full
Increased Expression of Hypoxia-Inducible Factor 1α in Coeliac Disease
https://www.nature.com/articles/pr2010143
Peroxiredoxins and Hypoxia-Inducible Factor-1α in Duodenal Tissue: Emerging Factors in the Pathophysiology of Pediatric Celiac Disease Patients
https://pmc.ncbi.nlm.nih.gov/articles/PMC9954839/
I recently sprang for a ChatGPT5 subscription just to play with it and have found it to be a revelation. ChatGPT5 has become my new best friend helping me to explore and answer questions that have been nagging me sometimes for years.
Of course our conversation turned to hookworms and celiac disease as well as my other condition, ulcerative colitis. ChatGPT5 had an awful lot to say on the topic and was able to summarize past research for me and tell me where future research is going. Here's an example of one of our conversations:
Me: Earlier I asked you about why I have had such a good response with hookworms putting my ulcerative colitis and celiac disease into remission. Can you bring that information up again for me?
ChatGPT said: Of course, Pete — here’s the recap of what we explored earlier about why hookworms (Necator americanus) may have put your ulcerative colitis and celiac disease into remission:
🌱 The Hygiene Hypothesis
Modern life in highly sanitized environments may deprive our immune system of the “training” it evolved with. Helminths (like hookworms) were once common in humans; without them, immune systems may overreact to harmless things, leading to autoimmune and inflammatory diseases.
🧬 Immune System Modulation
Hookworms secrete proteins and molecules that dampen inflammation. They can shift the immune response away from aggressive, damaging pathways (like Th1 and Th17 cells, which drive colitis and celiac inflammation). They promote regulatory T cells (Tregs), which calm the immune system and help restore balance.
🔗 Gut Barrier & Microbiome Effects
Hookworms may strengthen the gut barrier, reducing “leaky gut” phenomena that can worsen autoimmunity. They also influence the gut microbiome, encouraging a more tolerant, less inflammatory environment.
⚖️ Why It Worked for You
In celiac disease, the immune system attacks gluten proteins. By calming your immune response and boosting tolerance, hookworms likely reduced or eliminated that reaction. In ulcerative colitis, chronic inflammation of the colon is the problem. Hookworm-induced immune modulation may have quieted the overreaction and allowed remission. Not everyone responds as dramatically, but your case fits the “super-responder” profile seen in some trials and reports.
✅ In short: Hookworms likely created a more tolerant, balanced immune environment in your gut — calming the hyperactive responses that once caused violent gluten reactions and severe ulcerative colitis flares.
Would you like me to also summarize what current research says about personalized helminth therapy (tailoring parasite type/dose to each individual), since you had such a strong positive response?
You said:
yes
ChatGPT said: Here’s a focused, research-backed look at what “personalized” helminth therapy could mean—and where the science is today—especially relevant to Necator americanus and your UC/Celiac story.
What “personalized helminth therapy” would tune
Species & product
Live worms vs. worm-derived molecules (secreted proteins/peptides) that mimic the immunoregulation without infection. There’s active work to identify and standardize these molecules for future precision use. PMC+2ScienceDirect+2
Dose & worm burden
Trials in celiac disease typically used 20–40 infective L3 hookworm larvae, with stepwise gluten challenges to test tolerance; responses vary by person. Newer work even measures gut worm burden (e.g., capsule endoscopy) to calibrate dose. PubMed+2Nature+2
Timing & schedule
Induction vs. maintenance dosing and how quickly to escalate exposure to the trigger (e.g., gluten) are key personalization knobs explored in hookworm–celiac studies. Nature
Patient biology & biomarkers
Baseline immune tone (Th1/Th17 overactivity), capacity to induce Tregs/IL-10, genetics (e.g., HLA-DQ2/8 in celiac), microbiome composition, and even “trained immunity” features likely influence who responds. Several 2024–2025 reviews argue future protocols should stratify patients by these markers. eLife+1
Disease context
Evidence is mixed across conditions: IBD and celiac have mechanistic plausibility and some positive signals; TSO (pig whipworm) meta-analyses in IBD show inconsistent efficacy, underlining the need to match organism/approach to the disease biology—not one-size-fits-all. PMC
What the clinical literature has shown so far
Hookworm–celiac trials: Multiple studies (including RCTs) show that controlled N. americanus infection can shift gluten immunity toward tolerance in some participants and permit limited gluten exposure with fewer symptoms—though not universally, and not yet as a standard therapy. PubMed+3PLOS+3ScienceDirect+3
IBD (UC/Crohn’s): Signals of benefit exist, but larger controlled data are still limited; a 2024 clinical paper and recent reviews reinforce the promise + heterogeneity theme (responders vs. non-responders). Oxford Academic+1
TSO in IBD: safety generally acceptable, efficacy mixed/neutral in pooled analyses—again arguing for tighter patient selection and endpoints. PMC
Why personalization matters (the mechanistic angle)
Helminths tend to:
Up-regulate regulatory pathways (Tregs, IL-10, TGF-β),
Down-modulate pro-inflammatory Th1/Th17,
Reshape the microbiome and strengthen barrier function.
But the magnitude of these effects varies person-to-person, so matching the right species/dose/timing to the right immune and microbiome baseline is likely the difference between a dramatic remission (like yours) and a flat result. Frontiers+2PMC+2
Where the field seems headed
From worms to defined molecules: Intense work is identifying helminth-derived proteins and glycans that reproduce the “tolerance” effect—more controllable, doseable, and potentially pairable with standard meds. Think of it as “helminth-inspired biologics.” PMC+1
Stratified trials: Reviews in 2024–2025 call for trials that pre-stratify by genetics, immune signatures, microbiome, and disease stage—i.e., genuine personalization rather than treating everyone the same. eLife
Objective monitoring: Tools to quantify worm burden and immunologic response (e.g., Treg/IL-10 assays, cytokine panels, microbiome metrics) will likely guide dosing and maintenance. Taylor & Francis Online
Practical takeaways for you (given your strong response)
Your history looks like a “responder phenotype”—meaning your immune system is highly amenable to helminth-driven regulation. In a personalized framework that would argue for:
Lowest effective burden that keeps symptoms in remission,
Periodic checks of iron status and general labs (hookworms can affect iron),
(If you ever switched to non-live options) interest in helminth-derived therapeutics once they’re available in trials.
If researchers were tailoring a protocol for someone like you, they’d likely characterize your baseline immune markers and microbiome to understand why you respond so well—and use that as a template for dosing/maintenance for you and others.
